Xeris Biopharma Holdings
XERS
92 hedge funds and large institutions have $120M invested in Xeris Biopharma Holdings in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 10 closing their positions.
250% more call options, than puts
Call options by funds: $6.72M | Put options by funds: $1.92M
230% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 10
180% more capital invested
Capital invested by funds: $42.9M → $120M (+$77.3M)
120% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 15
31% more funds holding
Funds holding: 70 → 92 (+22)
6.58% more ownership
Funds ownership: 26.34% → 32.91% (+6.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$13.6M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$12.2M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$7.02M |
| 4 |
Lazard Asset Management
New York
|
+$5.03M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
-$8.97M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$674K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$346K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$190K |
| 5 |
AGM
Alpine Global Management
New York
|
-$162K |
XERS Hedge Fund Activity: Q4 2021 in Review
92 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2021, worth a combined $120M — up 180% from $42.9M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new XERS positions and 10 closed out — a net gain of 23 holders — while 33 added to existing stakes and 15 trimmed.
The largest buyer was Caxton Corporation, opening a new position worth an estimated $13.6M. The largest seller was Sessa Capital, exiting entirely with an estimated $8.97M sold.
- 92 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2021, up from 70 in Q3 2021.
- Funds reported $120M of Xeris Biopharma Holdings stock for Q4 2021, up 180% quarter-over-quarter.
- 33 funds opened new Xeris Biopharma Holdings positions in Q4 2021 and 10 closed out, a net change of +23 holders.
- The largest Xeris Biopharma Holdings buyer in Q4 2021 was Caxton Corporation, an estimated $13.6M added.
- The largest Xeris Biopharma Holdings seller in Q4 2021 was Sessa Capital, an estimated $8.97M sold.
Based on aggregated 13F filings for Q4 2021.